ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
0.6120
-0.0110 (-1.77%)
At close: Apr 1, 2025, 4:00 PM
0.6080
-0.0040 (-0.65%)
After-hours: Apr 1, 2025, 7:24 PM EDT
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
80
Market Cap
32.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALXO News
- 26 days ago - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 27 days ago - ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event - GlobeNewsWire
- 4 weeks ago - ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - GlobeNewsWire
- 6 weeks ago - ALX Oncology to Host Virtual R&D Day on March 5, 2025 - GlobeNewsWire
- 2 months ago - ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - GlobeNewsWire
- 2 months ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 2 months ago - ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - GlobeNewsWire
- 3 months ago - ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire